Compounds > topotecan
Page last updated: 2024-08-24

topotecan and nu 1025

topotecan has been researched along with nu 1025 in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Almassy, RJ; Boritzki, TJ; Calabrese, CR; Calvert, AH; Curtin, NJ; Ekkers, A; Golding, BT; Griffin, RJ; Hostomsky, Z; Kumpf, RA; Kyle, S; Li, J; Maegley, KA; Newell, DR; Thomas, HD; Tikhe, JG; Wang, LZ; Webber, SE; Yu, XH; Zhang, C1
Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW1
Chianese, M; Cimmino, G; Laus, G; Penitente, R; Pepe, S; Prece, D; Quesada, P1
Carlomagno, C; Della Vittoria Scarpati, G; Ferrone, S; Fusciello, C; Leonardi, A; Pacelli, R; Pepe, S; Pepin, D; Poudel, R; Sabbatino, F; Somma, D1

Other Studies

4 other study(ies) available for topotecan and nu 1025

ArticleYear
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase.
    Journal of medicinal chemistry, 2004, Oct-21, Volume: 47, Issue:22

    Topics: Antineoplastic Agents; Azepines; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Models, Molecular; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Topoisomerase I Inhibitors

2004
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:7

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Temozolomide; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay

2000
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
    Pharmacological research, 2007, Volume: 55, Issue:1

    Topics: Apoptosis; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Densitometry; DNA Damage; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Glioblastoma; Humans; In Situ Nick-End Labeling; Indicators and Reagents; Mutation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Signal Transduction; Topotecan; Tumor Suppressor Protein p53

2007
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2014, Volume: 85, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Flow Cytometry; Glioblastoma; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Quinazolines; Radiation, Ionizing; Topoisomerase I Inhibitors; Topotecan; Tumor Suppressor Protein p53

2014